# OnCo record all-paediatric-relapsed (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/all-paediatric-relapsed/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "all-paediatric-relapsed" ;
  schema:name "Relapsed and refractory acute lymphoblastic leukaemia in children"@en ;
  schema:alternateName "Relapsed childhood ALL"@en, "Refractory paediatric B-ALL"@en, "Second-line childhood ALL"@en ;
  schema:description "When childhood leukaemia comes back, chemotherapy alone cures fewer than half. Three immune treatments changed this: blinatumomab, which links the child's T-cells to leukaemia cells and beat chemotherapy in two trials; tisagenlecleucel, the first approved CAR T-cell therapy, which put over eight in ten pretreated children into remission; and the antibody-drug conjugate inotuzumab ozogamicin."@en ;
  schema:url <https://onco.cc/cancers/all-paediatric-relapsed/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tisagenlecleucel> ;
  schema:citation <https://en.wikipedia.org/wiki/Tisagenlecleucel>, <https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq> ;
  onco:tag "subtype-page", "paediatric" ;
  onco:related <https://onco.cc/cancers/all-paediatric-standard-risk/>, <https://onco.cc/cancers/all-paediatric-high-risk/>, <https://onco.cc/cancers/all-infant/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd22/>, <https://onco.cc/targets/cd3/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/mrd/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-eliana-tisagenlecleucel-nejm-2018/> ;
  onco:pipeline <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/inotuzumab-ozogamicin/>, <https://onco.cc/drugs/obecabtagene-autoleucel/>, <https://onco.cc/trials/felix/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/drugs/venetoclax/> ;
  onco:standardOfCare <https://onco.cc/drugs/mitoxantrone/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/asparaginase/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/trials/eliana/>, <https://onco.cc/drugs/inotuzumab-ozogamicin/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/nelarabine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/trials/augment-101/>, <https://onco.cc/technologies/allogeneic-hsct/> .